Nuria Pardo Aranda

RT @StephenVLiu: A busy #ESMO25 warrants an episode of the @IASLC podcast, Lung Cancer Considered, to help highlight some of the new data! Watch next week for this episode with Drs. @LeXiuning @DrRiyazShah @pedrofsrocha!

RT @DrMirallas: 🙌🏽 Back to back sessions at #ESMO25 by @pedrofsrocha 💥 📌 DeLLphi-304 Tarlatamab 2L for #SCLC ORR 33-37% irrespective of CFI ⬇️ Risk of death HR 0.60 ☣️ Lower tox! 📌 IDeate-Lung01: intracranial activity of ifinatamab deruxtecan (IDXd) ✔️ ORR 46% @OncoAlert @myESMO @_SEOM

RT @StephenVLiu: Congratulations to the winner of the @IASLC 2025 Daniel C. Ihde Lectureship Award for Medical Oncology at #WCLC25 - Dr. @HendriksLizza - who reminds us of the need to rethink trial eligibility to answer relevant questions and to make lung cancer research sustainable.

RT @JordiRemon: HARMONi: Ivonescimab+CT ⬆️ PFS vs CT in post-osi EGFRm NSCLC.Qx: -How and when to place this strategy based new SoC 1st line? -Control arm trial was CT not CT+Ami -Data support Ivonescimab in EGFRm (table) -What EGFRm obtain higher benefit of IVO? Predictive biomarkers #WCLC2025

RT @StephenVLiu: Chemotherapy duration shown here - and fairly high crossover rates are reassuring. More toxicity, yes, but no new signals seen here. Question remains - which regimen for which patient? But a very welcome advance and impressive presentation from @dplanchard at #WCLC25.

RT @JordiRemon: FLAURA2 trial: Osi + CT improves PFS & OS (⬇️ 23% risk death) vs Osi alone in mEGFR NSCLC. Qx: -Intensification for all pts? Benefit in some subgroups only (Brain) -Chemo or ami for intensification?toxicity QoL, relevant for decisions -Cost -Is Osi alone no more valid? #WCLC2025

RT @DrMirallas: 🤩 Thanks for passing by, photos with both #phaseI and #thoracic group at @VHIO Interesting work presented at the #drugdevelopment poster session 🔥 🙌🏽 An incredible #ASCO25 @ASCO @OncoAlert @myESMO @_SEOM #OncoNexion25

RT @DrMirallas: #ASCO25 Day2: Poster session #GI and #lungcancer @VHIO representation @ASCO 🙌🏽🎉 #OncoNexion25 @_SEOM @myESMO @OncoAlert @OncBrothers

RT @DrMirallas: 💥 Overview of #NSCLC after #ESMO24 🙌🏽 Organized by @EnriquetaFelip @EnriquetaFelip 🎉👏🏽Congratulations to all my colleagues for the brilliant speeches 🙏🏽 Thanks for the kind invitation #lungcancer #Oncology

RT @DrMirallas: #ESMO24 🫁 Track #Barcelona auditorium 🪑 @BenjaminBesseMD 👉🏽GALAXIES-LUNG201: Belrestotug+Dostarlimab ORR 65.6% No PFS 👉🏽RELATIVITY-104: Nivo vs Nivo+Rela ❌ITT: PFS 8.8m, ORR 46% ✔️ ADK+PDL1>1%(non-planned) PFS 9.8 vs 5.5ma. ORR 60.7% 👏🏼🙌🏽 Great discussion @GarassinoMarina

RT @DrJNaidoo: Sotorasib is a Pan-RASG12C-, with activity in NRASG12C+ cancers ⁦@CD_AACR⁩: - sotorasib 5x ⬆️potent against NRASG12C vs KRASG12C or HRASG12C (activity in all) - pt w NRASG12C+ CRC had prolonged response to soto+panitumumab ⁦@OncoAlert⁩ #LCSM

RT @DrMirallas: #SEOM22 Revisión del tratamiento de #cabezaycuello #HNSCC por Dra. Basté 📌 Sala Castilla 🕖 19:00h @_SEOM 👇🏼

RT @JordiRemon: Luckily 2021 = Relevant year 💥 for new treatment approvals in aNSCLC🫁 (some approved in early stage). For 2022 📕✏️: not need more “me too” drugs⛔️; need new agents at the time of PD based on resist mechanisms (not easy!!) & less inequities (fig. not perfect!) @OncoAlert #LUNG

RT @JordiRemon: Immunotherapy works in almost all thoracic malignancies including MPM 👏🏻👏🏻. Its role in thymic malignancies (rare and orphan) deserves further evaluation despite NIVOTHYM trial reported meaningful clinical data. Good for having clinical trials ongoing #ESMO21 @OncoAlert

RT @Bayern_Broncos: @goal It's a disgrace they're restarting the game.

RT @jsoriamd: Check out a great review summarizing the growth and clinical benefit of anti-cancer compounds in lung cancer @NatRevClinOncol

RT @AlxMtzMarti: #MIR2021 ¿Por qué especializarte en #OncologíaMédica en @vallhebron? Porque el trabajo en equipo es una realidad ⁦@VHIO⁩ ⁦@vallhebron⁩ Si quieres saber más, ven a la Jornada virtual de puertas abiertas: ⁦

RT @fpa_que: Cata a ciegas. @diariodelvino #vinsdesdieux

RT @JordiRemon: In B3-Thymoma & Thymic Carcinoma, ICIs are NOT ⛔️ SoC. Efficacy similar to other strategies available, but risk of severe toxicity ❤️(9% myocarditis). No predictive biomarkers 🎯. Lot of ongoing trials ongoing 👏🏻 will define role ICI in TET, probably combos #ELCC21 @OncoAlert

RT @JordiRemon: PECATI Trial,lenvatinib plus pembrolizumab (20/200) a potential ttx for pts w metastatic pretreated B3-Thymoma or TC -mPFS 14.9mo -ORR: 23.3% -1-y OS: 85.2% -G3 irAEs: 14% -Keep Dose intensity lenva first 8 weeks ⬆️ PFS Thanks to all authors!! DOI: 10.1016/S1470-2045(25)00300-6